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Epstein-Barr virus-related post-transplant lymphoproliferative disor-ders are recognized as a significant cause of morbidity and mortal-ity in patients undergoing hematopoietic stem cell transplantation.
To better define current understanding of post-transplant lymphoprolif-
erative disorders in stem cell transplant patients, and to improve its diag-
nosis and management, a working group of the Sixth European
Conference on Infections in Leukemia 2015 reviewed the literature,
graded the available quality of evidence, and developed evidence-based
recommendations for diagnosis, prevention, prophylaxis and therapy of
post-transplant lymphoproliferative disorders exclusively in the stem
cell transplant setting. The key elements in diagnosis include non-inva-
sive and invasive methods. The former are based on quantitative viral
load measurement and imaging with positron emission tomography;
the latter with tissue biopsy for histopathology and detection of
Epstein-Barr virus. The diagnosis of post-transplant lymphoproliferative
disorder can be established on a proven or probable level. Therapeutic
strategies include prophylaxis, preemptive therapy and targeted thera-
py. Rituximab, reduction of immunosuppression and Epstein-Barr virus-
specific cytotoxic T-cell therapy are recommended as first-line therapy,
whilst unselected donor lymphocyte infusions or chemotherapy are
options as second-line therapy; other methods including antiviral drugs
are discouraged.
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ABSTRACT
Introduction
Post-transplant lymphoproliferative disorders (PTLD)
are a heterogeneous group of diseases occurring in the set-
ting of transplantation of either hematopoietic stem cells
(HSCT) or solid organs (SOT). PTLD results from the
uncontrolled neoplastic proliferation of lymphoid or plas-
macytic cells. It can occur at any age and after all types of
transplant; recipients of allogeneic HSCT are at a particu-
lar risk for developing PTLD.1,2 In contrast to the SOT set-
ting, post-HSCT PTLD are almost exclusively EBV-related,
although rare cases of non-EBV-PTLD also exist in this set-
ting. PTLD is one of the most severe complications associ-
ated with transplantation. Before 2000, an attributable
mortality for PTLD of 84.6% after HSCT was reported.1
With the introduction of new approaches for EBV dis-
ease/PTLD, including the use of monitoring for EBV by
PCR, pre-emptive therapy and timely treatment with rit-
uximab, considerable improvements in outcome have
been achieved. However, mortality remains high; approx-
imately one-third of diagnosed patients.3
Recently, guidelines for management of PTLD in the
SOT setting were published.4-6 The first recommendations
for management of EBV infections in patients undergoing
HSCT or therapy for hematological malignancies were
produced following the Second European Conference on
Infections in Leukemia (ECIL-2) in 2007.7 The goal of this
paper is to present updated recommendations based on
analysis of recent data.
Methods
The main task of ECIL is to develop evidence-based
guidelines for management of infectious complications in
subjects with leukemia including HSCT. An EBV-PTLD
Working Group was hence created. The group defined the
relevant issues, questions and outcomes to be addressed,
and evaluated these issues and questions prior to the con-
sensus conference through a systematic literature review.8
PubMed was searched using each of the following terms:
lymphoproliferative disorder, PTLD, Epstein-Barr virus,
EBV, together with leukemia, hematopoietic transplanta-
tion, HSCT, bone marrow transplantation, or cord blood.
Relevant studies were reviewed up to August 2015.
Recommendations were elaborated within the group and
graded for quality of evidence (I–III) and strength of rec-
ommendation (A–D) using the ESCMID/EFISG grading
system (Table 1).9
The ECIL-6 conference (September 11-12, 2015) was
attended by 55 experts from 25 countries, including 16
European countries. Experts in hematology, microbiology,
and infectious diseases were mostly selected for their
active participation in the host organizations. The group
presented its literature review and guideline proposals in
plenary session. After panel debate, the recommendations
were revised as necessary until reaching a final consensus.
Definitions and diagnostic criteria
Primary EBV infection is defined when EBV is detected
(nucleic acid or serologically) in an EBV-naïve individual
(most often asymptomatic acquisition, or occasionally
presenting as infectious mononucleosis). Recurrent EBV
DNA-emia is diagnosed by detection of EBV DNA in the
blood of a previously infected individual, as defined by
detection of EBV-specific IgG-antibodies. EBV-associated
disease following transplantation can be categorized as
EBV-PTLD or other EBV-associated post-transplant mani-
festations; also referred to as EBV end-organ disease. 
EBV-PTLD can be diagnosed as probable or proven.
Probable EBV disease: significant lymphadenopathy,
hepatosplenomegaly or other end-organ manifestations
(without tissue biopsy, but in the absence of other docu-
mented cause), together with significant EBV DNA-emia.
Proven EBV disease: detection of EBV nucleic acids or
EBV-encoded proteins in a tissue specimen, together with
symptoms and/or signs from the affected organ. 
The diagnosis of EBV-PTLD should be based on at least
two of the following histological features: (i) disruption of
underlying cellular architecture by a lymphoproliferative
process, (ii) presence of monoclonal or oligoclonal cell
populations as revealed by cellular and/or viral markers,
(iii) evidence of EBV infection in many of the cells i.e.
DNA, RNA or protein. Detection of EBV nucleic acid in
blood is not, eo ipso, sufficient for the diagnosis of EBV-
PTLD. 
The recommended method for histological specimens,
conferring high sensitivity and specificity, is the detection
of EBV-encoded RNA by in situ hybridization (EBER-ISH).
Immunohistochemistry for viral proteins have good speci-
ficity but lower sensitivity; these proteins are variably
expressed in PTLD biopsies. Detection of EBV DNA by
PCR of histological extracts is not an appropriate method
for PTLD diagnosis given the very high sensitivity but low
positive predictive value (PPV) (Table 2).10-15
The histopathologic criteria of PTLD were defined by
Swerdlow and Greig.16 The WHO classification is most
commonly used, with four types of morphological lesions
being recognized: polyclonal early lesions, polymorphic,
monomorphic (B-cell or T/NK-cell) and classical Hodgkin
lymphoma-type PTLD.17 
Epidemiology
The incidence of EBV DNA-emia and EBV-PTLD varies
between transplant centers. The reported incidence of
EBV DNA-emia ranging between 0.1-63% is largely
dependent on the type of transplant, assay sensitivity,
defined level of DNA-emia, use of systematic screening
and its timing.18-27  
In a recent EBMT study, the overall incidence of PTLD
after allogeneic HSCT was 3.2%, varying from 1.2% in
matched family donor (MFD) to 2.8% in mismatched
family donor (haploidentical/MMFD), 4.0% in matched
unrelated donor (MUD), and 11.2% in mismatched unre-
lated donor (MMUD) recipients.3 In recipients of unrelated
cord blood (CBT), the incidence of EBV-PTLD was 2.6-
3.3% for myeloablative transplants, and 7-12.9% in non-
myeloablative transplants.24,28 Interestingly, data from
haplo-HSCT incorporating post-transplant cyclophos-
phamide (haplo-PTCy-HSCT) indicate a very low EBV-
PTLD incidence.23 The median time to development of
EBV-PTLD after HSCT is 2-4 months.3,29 Only 4% of cases
develop later than 12 months after HSCT, and cases occur-
ring >5 years after HSCT are extremely rare.3 PTLD after
autologous-HSCT is very rare.30-32
Risk factors for EBV-PTLD
Risk factors for developing EBV-PTLD can be considered
as existing pre-20,24,33-35 or developing post-transplant7,34-37
(Table 3). Importantly, assessing the risk of EBV-PTLD is
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dependent on the HSCT context with potentially complex
interactions between the primary hematological malig-
nancy, HSCT procedure, source, and other factors. Given
that the risk of EBV-PTLD is predominantly related to the
degree of T-cell depletion or impairment, this should be
regarded as the principal risk factor (AIIu). Strategies that
deplete T cells from the graft increase the risk of EBV-
PTLD.38
CBT confers an intrinsic risk for EBV-PTLD because of
T-cell naïvety related to the HSC source. A high incidence
of EBV-PTLD in both pediatric and adult patients after
CBT, following reduced intensity conditioning regimens
using anti-thymocyte globulin (ATG) or alemtuzumab
(anti-CD52), has also been reported.28,39 This likely reflects
both the delayed recovery of EBV-specific CTLs after such
transplants, alongside the persistence of recipient-derived
B cells. The use of alemtuzumab during conditioning in
other types of HSCT can also be regarded as a risk factor
for EBV-PTLD.27,29 There appears to be a dose-dependent
risk with the in vivo use of ATG in children,40 which is
probable also in adults. Current data do not suggest any
significant differences between children and adults with
respect to epidemiology and risk factors. 
Patients undergoing HSCT can be classified for the risk
for EBV-PTLD as low risk (auto-HSCT), standard risk
(MFD allo-HSCT without risk factors, haplo-PTCy-
HSCT), and high risk (MFD with at least one risk factor,
MUD/MMUD, alternative donors including CBT).
ECIL recommendations for prevention of EBV diseases
including PTLD
ECIL recommends that all allo-HSCT patients and
donors should be tested for EBV antibodies before trans-
plantation (Table 4). Since EBV sero-mismatch is a risk fac-
tor for PTLD,34,35 the selection of an EBV matched donor, if
possible, might be beneficial. As EBV-PTLD after HSCT is
usually of donor origin and EBV might be transmitted
with the graft, the risk of EBV-PTLD is higher when the
donor is seropositive. Neither in vivo/ex vivo CD34-positive
selection nor CD3/CD19 depletion prevents EBV-
PTLD.11,31 Allo-HSCT recipients should be closely moni-
tored clinically, together with prospective monitoring for
EBV DNA in peripheral blood. Importantly, monitoring
and intervention strategies might be individualized,
informed by a holistic assessment of EBV-PTLD risk. 
ECIL recommendations for diagnosis and monitoring 
of EBV DNA-emia
Prospective monitoring of EBV DNA performed by
quantitative PCR is recommended. There are no data to
support a preference for whole blood, plasma or serum; all
are appropriate specimens for monitoring EBV DNA-
emia.7,41-43
Screening for EBV DNA-emia should start within the first
month after allo-HSCT. However, the incidence of EBV-
PTLD during the first month after HSCT is estimated to be
below 0.2%.3 Monitoring should continue for at least 4
months after HSCT, with a frequency of at least once a
week. As the calculated doubling time for EBV might be as
short as 56 hours,44 more frequent sampling in patients with
rising EBV DNA-emia may be warranted (Table 5). 
ECIL recommendations for diagnosis 
of EBV-disease/PTLD
Fever and lymphadenopathy are the most common
symptoms and signs of EBV-PTLD and are, if not treated,
ECIL-6 guidelines for EBV-PTLD after HSCT
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Table 1. ECIL-6 scoring system.
Strength of Recommendation (SoR)* Definition
Grade A ECIL strongly supports a recommendation for use
Grade B ECIL moderately supports a recommendation for use
Grade C ECIL marginally supports a recommendation for use
Grade D ECIL supports a recommendation against use
Quality of Evidence (QoE) Definition
Level I Evidence from at least 1 properly designed, randomized, controlled trial (orientated 
on the primary endpoint of the trial)
Level II Evidence from at least 1 well-designed clinical trial (including secondary endpoints), 
without randomization; from cohort or case-controlled analytic 
studies (preferably from > 1 center; from multiple time series; 
or from dramatic results of uncontrolled experiments
Level III Evidence from opinions of respected authorities, based on clinical experience, 
descriptive case studies, or reports of expert committees
Added Index Source of Level II Evidence
r Meta-analysis or systematic review of RCT
t Transferred evidence: data from different patient cohorts with comparable 
clinical features and/or immune function
h Comparator group: historical control
u Uncontrolled trials
a Published abstract presented at an international symposium or meeting
*poor quality of design, inconsistency of results, indirectness of evidence etc. would lower the SoR. 
frequently associated with rapidly progressive multi-organ
failure and death.45 The diagnostic approach to EBV-PTLD
should, preferably, be based on biopsies of enlarged lymph
nodes and other sites of suspected EBV disease (Table 5).
However, if this is impossible due to the clinical status of
the patient, a non-invasive approach, encompassing quan-
titative EBV DNA-emia combined with PET-CT/CT imag-
ing, can be considered.29,46,47
The diagnostic work-up of EBV-PTLD includes: (a)
physical examination, including an examination for fever,
tonsillitis, adenopathy and organomegaly; (b) PET-CT/CT
imaging; (c) endoscopy in case of gastro-intestinal symp-
toms; (d) tissue biopsy with histological examination,
including EBER ISH and/or immunohistochemistry for
viral antigens, and/or flow cytometry; (e) peripheral blood
EBV viral load by PCR. 
The clinical staging of EBV-PTLD includes: nodal vs.
extranodal, limited (unifocal) vs. advanced (multifocal) dis-
ease.3 The Ann Arbor classification, established for staging
of lymphoma, can also be recommended. As PTLD is an
FDG-avid malignancy, EBV-PTLD can be staged according
to the Lugano classification by PET-CT, both in children
and adults.47-50
Management strategies
There are three approaches for EBV infection, EBV dis-
ease and EBV-PTLD after HSCT: prophylaxis, pre-emptive
therapy and treatment of EBV disease/PTLD.  Prophylaxis
of EBV disease includes any intervention (e.g. drug or cel-
lular therapy) given to an asymptomatic EBV-seropositive
patient to prevent EBV DNA-emia. Pre-emptive therapy
includes any intervention given to a patient with EBV
DNA-emia to prevent EBV disease. Treatment of EBV dis-
ease includes therapeutic interventions for patients with
probable or proven EBV disease.
Prophylaxis and treatment approaches of EBV-PTLD
include: administration of rituximab (anti-CD20 mono-
clonal antibodies), reduction of immunosuppression (RI),
EBV-CTL, donor lymphocyte infusion (DLI) and
chemotherapy. RI is defined as a sustained decrease of at
least 20% of the daily dose of immunosuppressive drugs
with the exception of low-dose corticosteroid therapy.21
Pooling results from published studies in HSCT recipi-
ents suggest that administration of rituximab results in a
positive outcome for approximately 90% patients treated
pre-emptively, and 65% with EBV-PTLD.2,3,11,12,19,20,24,27,51-62
Recent data demonstrate that RI, when applied in combi-
nation with rituximab, appears to improve the outcome
by over 80%.3 RI used alone as preemptive therapy result-
ed in a 68% success rate.21,51 The use of EBV-CTLs leads to
a positive outcome for >90% of patients treated pre-emp-
tively, and approximately 75% in therapy of EBV-
PTLD.51,63-68 There are no studies directly comparing effica-
cy of rituximab±RI vs. EBV-CTL in either prophylaxis, pre-
emptive or targeted therapy. Thus, there is insufficient evi-
dence to support a recommendation for one treatment
modality over another as a first line approach for centers
with access to both therapies.
ECIL recommendations for prophylaxis of EBV 
DNA-emia
Rituximab. B-cell depletion by prophylactic use of ritux-
imab before or shortly after allo-HSCT might reduce the
risk of EBV DNA-emia and PTLD (Table 6).20,23,69,70 In a
large retrospective analysis, prophylactic post-transplant
rituximab significantly reduced the risk of EBV DNA-
emia; however, no statistically significant impact on PTLD
incidence, treatment-related mortality, and overall survival
in comparison to a pre-emptive approach was demonstra-
ble.69 Low risk of EBV-PTLD was observed also after the
use of post-transplant high-dose cyclophosphamide,23 or
sirolimus as GvHD prophylaxis.20 Since rituximab treat-
ment after allo-HSCT has been related to an increased risk
of life-threatening cytopenias71 and bacterial infections,72
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Table 2. Relative merits of EBV assays. 
Assay Material Value Recommendation Reference
DNA by PCR Whole blood, high sensitivity AIIu 10-12
plasma, serum and specificity, low PPV 
Tissue specimen very high sensitivity but low PPV DIIu 13
EBER ISH Tissue specimen high sensitivity and specificity AIIu 14
Viral proteins Tissue specimen high specificity but lower CIII 15
(e.g. LMP1 sensitivity; variably expressed
and EBNA1) in PTLD biopsies
Table 3. Risk factors for EBV-PTLD after HSCT.
Pre-transplant risk factors
• T-cell depletion (either in vivo or ex vivo) 
• EBV serology donor/recipient mismatch 
• Cord blood transplantation (CBT)
• HLA mismatch 
• Splenectomy
• Second HSCT
Post-transplant risk factors
• Severe acute (especially steroid-refractory) or chronic GvHD requiring intensive immunosuppressive therapy 
• High or rising EBV viral load
• Treatment with mesenchymal stem cells
the use of rituximab should be restricted to patients at
highest risk of EBV-PTLD and, following its use, accompa-
nied by close monitoring for hypogammaglobulinemia
with consideration of Ig replacement and other strategies
to limit infectious-related mortality.
EBV-CTLs. High efficacy of prophylaxis has been
shown with the use of EBV-CTLs in a high-risk group in
one study.63 Current use of EBV-CTLs is, however, limited
as it is available only in selected centers.
Antiviral drugs. Although aciclovir, ganciclovir, foscarnet,
and cidofovir show some in vitro activity against replicat-
ing EBV,73 antiviral treatment of latent EBV has been
unsuccessful74 since latently infected B cells do not express
the EBV thymidine kinase enzyme transcript or protein.
There is no evidence to recommend any anti-EBV antiviral
prophylaxis in patients with hematological malignancies
in non-allo-HSCT setting (DIII). 
ECIL recommendations for preemptive therapy against
EBV disease
Indications. The indication for preemptive therapy is sig-
nificant EBV DNA-emia without clinical symptoms/dis-
ease in patients with high risk for EBV-PTLD (Table 7).
The goal of preemptive therapy is to obtain a negative
EBV PCR or EBV DNA-emia below the initial threshold
without relapse.
Implications of EBV DNA-emia. EBV DNA-emia mostly
occurs prior to the onset of clinical symptoms but data are
somewhat conflicting.7,75-78 Currently available data do not
allow elucidation of an EBV-DNA threshold for the devel-
opment of EBV disease. Indeed, probable/proven PTLD
has been described in a significant proportion of patients
with EBV DNA levels below commonly adopted interven-
tion thresholds.29 
Threshold value. In the absence of universal standards for
Nucleic Acid Test assays, ECIL cannot recommend a specif-
ic threshold value of EBV DNA-emia for giving preemptive
therapy. Some authors employ a threshold of 1,000 EBV
copies/mL,10,11,20 10,000 EBV copies/mL,2,12,34,37 or 40,000 EBV
copies/mL19,27 when determined in whole blood, plasma,
serum; or 1,000 copies as determined per 105 PBMC69 to ini-
tiate pre-emptive therapy. The rate of increase of EBV copy
number is likely to be clinically significant given that
increases in EBV DNA-emia are due to the expansion of
EBV-infected memory B cells in the peripheral blood. Local
experience based on correlation of clinical and laboratory
data might be a rationale for center-specific cut-off value. 
Rituximab. The primary method for preemptive therapy
is rituximab, dose 375 mg/m2, once weekly until EBV
DNA-emia negativity. The number of doses should be
assessed locally on the basis of changes in EBV DNA-emia
and an assessment of the patient’s immune function.
Typically, 1-4 doses are sufficient.
Reduction of immunosuppression. Rituximab should be
ECIL-6 guidelines for EBV-PTLD after HSCT
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Table 4. Recommendations for prevention of EBV disease after HSCT.
Allo-HSCT patients
• All allo-HSCT patients and donors should be tested before transplantation for EBV antibodies (AIIu). 
• For an EBV-seronegative patient, an EBV-seronegative donor is preferred (BIIu).
• For an EBV-seropositive recipient, an EBV-seropositive donor might be beneficial, due to the presence of  EBV-positive CTLs (CIII).
• Patients at high risk for EBV-PTLD after allo-HSCT should be closely monitored for symptoms or signs attributable to PTLD or other end-organ 
EBV disease (AIIu). 
• After high-risk allo-HSCT, prospective monitoring of EBV DNA-emia is recommended (AIIu).
• The risk in HLA-identical family transplant recipients not receiving T-cell depletion and without GvHD is low and no routine screening for EBV is 
recommended (DIIu).
Auto-HSCT or conventional chemotherapy patients
• It is not recommended that auto-HSCT patients be routinely monitored for EBV before and after HSCT (DIII).
• It is not recommended that conventional chemotherapy patients be routinely monitored for EBV before and during treatment (DIII).
Table 5. Recommendations for diagnosis of EBV DNA-emia and EBV-disease/PTLD.
Recommendations for diagnosis of EBV DNA-emia
• Prospective screening of EBV DNA-emia by quantitative PCR is recommended after allo-HSCT at high-risk for EBV-PTLD (AIIu). 
• Whole blood, plasma and serum are all appropriate biological specimens for monitoring EBV DNA-emia (BIIu). 
• Beginning of screening: no later than 4 weeks after the day of HSCT; in patients with several risk factors earlier screening might be considered (AIIu).
• Frequency of screening: testing for EBV DNA is recommended once a week in high-risk EBV PCR-negative patients (BIIu); in patients with rising EBV
DNA-emia more frequent sampling might be considered (BIIu).
• End of screening: at least 4 months after HSCT in high risk patients (BIIu).
• Longer monitoring is recommended in patients considered to have poor T-cell reconstitution: on treatment for severe acute/chronic GvHD, after haplo
HSCT, with the use of TCD, after conditioning with ATG/alemtuzumab, or in those having experienced an early EBV reactivation (BIIu).
Recommendations for diagnosis of EBV-disease/PTLD
• The diagnosis of EBV-PTLD must be based on symptoms and/or signs consistent with PTLD together with detection of EBV by an appropriate method
applied to a specimen from the involved tissue (AIIu).
• Non-invasive methods: quantitative EBV DNA-emia (in blood, plasma or serum) (AIIu), and PET-CT/CT (BIIt). PET-CT is preferred to CT in extranodal 
disease (BIII).
• Invasive methods: biopsy of lymph node and/or other sites suspected for EBV disease (AIIu).
• Diagnosis of proven EBV-PTLD requires biopsy and histological examination with EBV detection (AIIu).
• EBV detection requires in situ hybridization for the EBER transcripts or detection of viral antigens (AIIu). 
combined with RI, if possible, except in patients with
uncontrolled severe acute or chronic GvHD. 
Other options. Donor or third party EBV-specific cytotox-
ic T lymphocytes (CTL) are highly efficacious; however,
this approach is not widely available. Antiviral drugs are
not effective against EBV. 
ECIL recommendations for treatment of EBV-PTLD
First line therapy. In case of proven or probable EBV-
PTLD, therapy should be started as soon as practicable
due to the risk of a rapidly growing high-grade lymphoid
tumor, together with the risk of multi-organ impairment.
Rituximab monotherapy is the treatment of choice for
EBV-PTLD (Table 8) with positive outcome reported in
almost 70% of patients. Rituximab is usually administered
once weekly for up to 4 doses while monitoring EBV viral
load. Additional doses might result in down-regulation of
CD20 expression and thereby possibly decreased efficacy.
Reduction of immunosuppression (RI) is rarely successful
as the sole intervention in PTLD following HSCT,21,79 and
may increase the risk of rejection or GvHD.77 It should be
combined with rituximab administration.3 Additionally,
rituximab may reduce the risk of acute/chronic GvHD.80,81
Central nervous system (CNS) EBV disease. CNS localisa-
tion of EBV-PTLD warrants special consideration due to
the risk of neurocognitive dysfunction, notwithstanding
the successful eradication of EBV-infected cells from the
CNS. To date, no standard therapy has been accepted.
Possible therapeutic options include: (i) chemotherapy±rit-
uximab in line with primary CNS lymphoma protocols
based on high dose methotrexate and/or cytarabine82 or
hydroxyurea;83 (ii) monotherapy with rituximab, either
systemic3,84 or intrathecal;85 (iii) T-cell therapy with EBV-
specific CTLs;63,68 (iv) radiotherapy. 
Response to therapy. The treatment goal is resolution of all
signs and symptoms of PTLD, including a negative viral
load. Response to rituximab therapy can be identified by
a decrease in EBV DNA-emia of at least 1 log10 in the first
week of treatment (BIIh). Younger age is a favourable fac-
tor predicting outcome to rituximab-based therapy.
Positive prognostic factors for outcome to rituximab ther-
apy include: age below 30 years, underlying non-malig-
nant disease, no acute GvHD, RI at EBV-PTLD diagnosis,
and decrease of EBV DNA-emia after initial therapy.3
Second line therapy. In the setting of rituximab failure,
second-line therapy options include cellular therapy (DLI
or CTLs) or chemotherapy±rituximab. Unselected DLI
from an EBV-positive donor are employed to restore
broad T-cell reactivity, including EBV-specific responses;
unselected DLI, however, can be associated with severe
GvHD.86,87 Previous GvHD is usually a contraindication
to DLI. ECIL’s preferred approach is specific cellular ther-
apy; however, EBV-specific CTLs are not readily avail-
able in all centers. Apart from donor-derived CTLs, the
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Table 6. Recommendations for prophylaxis against EBV disease.
Recommendations for prophylaxis against EBV disease
• B-cell depletion with prophylactic rituximab might reduce the risk of EBV DNA-emia (CIIu).
• Prophylactic use of EBV-CTLs should be considered as first line prophylactic treatment whenever possible (CIIu).
• There are no data to support any positive impact of antiviral drugs on the development of EBV-PTLD. Antiviral drugs are not recommended for EBV 
prophylaxis (DIIu).
•  Interferon and IVIG are not recommended for EBV prophylaxis (DIII).
Table 7. Recommendations for preemptive therapy of EBV disease.
Recommendations for preemptive therapy of EBV disease
• Significant EBV DNA-emia without clinical symptoms of EBV disease is an indication for preemptive therapy with rituximab (BIIu). 
• No specific threshold  of EBV DNA-emia can currently be recommended for initiation of preemptive therapy.
• Rituximab once weekly (1-4 doses) is recommended until EBV DNA-emia negativity (AIIu).
• Rituximab should be combined with reduction of immunosuppression, if possible (AIIu).
• Donor or third party EBV-specific cytotoxic T lymphocytes (CTL) should be considered, if available (CIIu).
•  Antiviral drugs are not recommended for preemptive therapy (DIIh).
Table 8. Recommendations for therapy of EBV-PTLD.
First line therapy in EBV-PTLD
1.  Rituximab, 375 mg/m2, once weekly (AIIu).
2. Reduction of immunosuppressive therapy combined with rituximab should always be considered, if possible (AIIu). 
3. Cellular therapy as adoptive immunotherapy with in vitro generated donor or third-party EBV-specific CTL, if available (CIIu). 
Second line therapy in EBV-PTLD
1.  Cellular therapy (EBV specific-CTLs or DLI) (BIII).
2. Chemotherapy±rituximab is a potential option after failure of other methods (CIIh).
3. Surgery, IVIG, interferon and antiviral agents are not recommended for therapy of PTLD (DIII) CNS EBV disease.
CNS EBV disease
• Therapeutic options in EBV-PTLD in central nervous system include: rituximab ± chemotherapy (BIIh), rituximab systemic or intrathecal monotherapy    
(CIII), anti-EBV T-cell therapy (CIII) or radiotherapy (CIII). 
novel development of 3rd party EBV-CTLs may represent
a promising option for the recipients of cord blood trans-
plant, or those who have EBV-negative donors and/or
donors who are unable to provide further donation for
cellular therapy.64,66-68 Data on efficacy of DLI or
chemotherapy in EBV-PTLD are limited. Chemotherapy
for EBV-PTLD after HSCT is not recommended as first-
line therapy due to poor tolerability in HSCT patients
and the risk of inducing neutropenia and graft failure.51
Chemotherapy for EBV-PTLD is therefore restricted for
refractory/relapsing cases.88
ECIL recommendations for treatment of EBV-negative
and/or T-PTLD
A growing number of cases of EBV-negative B-PTLD
have been reported, presenting late (>5 years) after trans-
plant. These cases should be regarded as malignant lym-
phoma, not PTLD, and treated with appropriate
chemotherapy protocols. T-PTLD after HSCT are
extremely rare, and also should be regarded as malignant
lymphoma and treated with appropriate chemotherapy
protocols. 
Possible future developments 
The possible future anti-EBV prophylaxis and/or thera-
pies include cellular therapy, new monoclonal antibodies
and new antivirals. Active immunization against EBV is
not available. Ex vivo-generated EBV-CTL have proved to
be an effective prophylactic measure, pre-emptive thera-
py, or treatment for PTLD post-HSCT. EBV-CTL can be
isolated and expanded ex vivo from EBV-seropositive stem
cell or third-party donors. Considering the recent success
and safety profile of obinutuzumab in CD20-positive
malignancies,89,90 novel anti-CD20 monoclonal antibodies
are possible candidates for future use in EBV-PTLD. The
possibility of new and experimental therapies for EBV-
PTLD has also recently emerged in the transplant setting,
including brentuximab vedotin, anti-CD30 antibodies.
Brincidofovir, a new, currently unlicensed antiviral agent,
has excellent antiviral activity against EBV in vitro.91 Further
study, however, is needed in order to establish whether
prophylaxis with this drug will be able to reduce the risk
of EBV replication and possibly EBV-PTLD.
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